Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity

Oncogene

Volumn 30, Issue 31, 2011, Pages 3468-3476

  Akita, H ^a   Nagano, H ^a   Takeda, Y ^a   Eguchi, H ^a   Wada, H ^a   Kobayashi, S ^a   Marubashi, S ^a   Tanemura, M ^a   Takahashi, H ^b   Ohigashi, H ^b   Tomita, Y ^b   Ishikawa, O ^b   Mori, M ^a   Doki, Y ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Ep CAM; invasion; pancreatic cancer; prognosis; surgery

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER SURGERY; CELL ACTIVITY; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

AGED; ANTIGENS, NEOPLASM; CARCINOMA; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79961166877     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.59     Document Type: Article

References (50)

1. Armstrong A, Eck SL. (2003). EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2: 320-326.
2. Balzar M, Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV. (1999a). The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 246: 108-121. (Pubitemid 29393751)
3. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. (1999b). The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77: 699-712.
4. Basak S, Speicher D, Eck S, Wunner W, Maul G, Simmons MS et al. (1998). Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst 90: 691-697. (Pubitemid 28222143)
5. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413. (Pubitemid 27251144)
6. Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S. (2001). Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet 92: 164-165. (Pubitemid 32304683)
7. Cirulli V, Crisa L, Beattie GM, Mally MI, Lopez AD, Fannon A et al. (1998). KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 140: 1519-1534. (Pubitemid 28152999)
8. Edwards DP, Grzyb KT, Dressler LG, Mansel RE, Zava DT, Sledge Jr GW et al. (1986). Monoclonal antibody identification and characterization of a Mr 43 000 membrane glycoprotein associated with human breast cancer. Cancer Res 46: 1306-1317. (Pubitemid 16048272)
9. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW et al. (2008). Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3496-3502.
10. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A et al. (2008). Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 61: 31-35. (Pubitemid 351158222)
11. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. (2000). Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981-1982.
12. Geer RJ, Brennan MF. (1993). Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165: 68-72;discussion 72-63.
13. Gonzalez B, Denzel S, Mack B, Conrad M, Gires O. (2009). EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells 27: 1782-1791.
14. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH, Nagtegaal ID. (2007). Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 20: 221-232. (Pubitemid 46422177)
15. Gumbiner BM. (1996). Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 84: 345-357. (Pubitemid 26058560)
16. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA et al. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25: 319-325. (Pubitemid 350003021)
17. Jojovic M, Adam E, Zangemeister-Wittke U, Schumacher U. (1998). Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice. Histochem J 30: 723-729. (Pubitemid 28551803)
18. Kahlert C, Weber H, Mogler C, Bergmann F, Schirmacher P, Kenngott HG et al. (2009). Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer 101: 457-464.
19. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. (1993). An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72: 2118-2123. (Pubitemid 23280135)
20. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y et al. (2007). Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol 30: 171-179.
21. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. (2007). Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037.
22. Li D, Xie K, Wolff R, Abbruzzese JL. (2004). Pancreatic cancer. Lancet 363: 1049-1057. (Pubitemid 38410779)
23. Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H, Fleuren GJ et al. (1996). Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148: 865-875. (Pubitemid 126660678)
24. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F et al. (1997). Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139: 1337-1348. (Pubitemid 27523219)
25. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G et al. (2010). Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 28: 1358-1365.
26. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. (1987). Immunohistochemical study of the expression of a Mr 34 000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 47: 2883-2891. (Pubitemid 17113431)
27. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. (2004). The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23: 5748-5758. (Pubitemid 39093020)
28. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. (1995). Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 221: 59-66.
29. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H et al. (2009). Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 100: 1647-1658.
30. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. (2007). Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama 297: 267-277. (Pubitemid 46143304)
31. Ogawa M, Yamamoto H, Nagano H, Miyake Y, Sugita Y, Hata T et al. (2004). Hepatic expression of ANG2 RNA in metastatic colorectal cancer. Hepatology 39: 528-539. (Pubitemid 38222195)
32. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA et al. (2004). EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824. (Pubitemid 39095582)
33. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders Jr RA et al. (2005). Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 27: 49-57.
34. Ross AH, Herlyn D, Iliopoulos D, Koprowski H. (1986). Isolation and characterization of a carcinoma-associated antigen. Biochem Biophys Res Commun 135: 297-303. (Pubitemid 16064002)
35. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA et al. (1996). A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-353. (Pubitemid 26246785)
36. Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE. (2009). Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res 69: 753-757.
37. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E et al. (2008). Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 14: 5849-5855.
38. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH et al. (2004). Epithelial cell adhesion molecule (KSA) expression: patho-biology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10: 2659-2669. (Pubitemid 38509139)
39. Sener SF, Fremgen A, Menck HR, Winchester DP. (1999). Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189: 1-7. (Pubitemid 29307735)
40. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA et al. (2000). Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4: 567-579.
41. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH. (2005). Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 92: 1767-1772. (Pubitemid 40756490)
42. Staley CA, Lee JE, Cleary KR, Abbruzzese JL, Fenoglio CJ, Rich TA et al. (1996). Preoperative chemoradiation, pancreaticoduodenec-tomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 171: 118-124; discussion 115-124. (Pubitemid 126349884)
43. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbers-dobler A, Verde PE et al. (2006). Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 6: 165.
44. Tai KY, Shiah SG, Shieh YS, Kao YR, Chi CY, Huang E et al. (2007). DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene 26: 3989-3997. (Pubitemid 46884302)
45. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. (2007). Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171: 386-395. (Pubitemid 47344671)
46. Tsujie M, Nakamori S, Okami J, Hayashi N, Hiraoka N, Nagano H et al. (2003). Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Exp Cell Res 289: 143-151. (Pubitemid 36993844)
47. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D et al. (2004). Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10: 3131-3136. (Pubitemid 38619694)
48. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. (2003). The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 163: 2139-2148. (Pubitemid 37466457)
49. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H et al. (2008). EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68: 1451-1461. (Pubitemid 351346853)
50. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. (1998). Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res 4: 2669-2676. (Pubitemid 28523492)